Benjamin Bakall MD PhD
Retinal Disease
Medical retina/Inherited retinal dystrophies
Join to View Full Profile
1750 E Glendale AvePhoenix, AZ 85020
Phone+1 602-242-4928
Dr. Bakall is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Iowa Hospitals and ClinicsFellowship, Medical Retina, 2011 - 2013
University of Arizona College of Medicine-TucsonResidency, Ophthalmology, 2008 - 2011- University of Arizona College of Medicine2007 - 2008
- University of Arizona College of MedicinePost-Doctoral Fellowship, 2005 - 2007
Uppsala University Faculty of MedicineClass of 2005
Uppsala UniversityPhD, 2003- University of Iowa Hospitals and ClinicsResidency, Ophthalmology
Certifications & Licensure
AZ State Medical License 2013 - 2026
IA State Medical License 2011 - 2018
OH State Medical License 2010 - 2011
American Board of Ophthalmology Ophthalmology
Publications & Presentations
PubMed
- Variants in CFAP410 cause a range of retinal and skeletal phenotypes.Ryan E Schmidt, Amy E Pohodich, David Birch, Kaylie Jones, Byron L Lam
NPJ Genomic Medicine. 2025-04-17 - 18 citationsClassification and Growth Rate of Chorioretinal Atrophy after Voretigene Neparvovec-Rzyl for RPE65-Mediated Retinal Degeneration.Nikhil Bommakanti, Benjamin K Young, Robert A Sisk, Audina M Berrocal, Jacque L Duncan
Ophthalmology. Retina. 2024-01-01 - 1 citationsEmerging Disease of the Desert: Rise of West Nile Virus Chorioretinitis in Arizona.Jamie L Odden, Dillan Patel, J Shepard Bryan, Benjamin Bakall, Rima Patel
Journal of Vitreoretinal Diseases. 2023-11-23
Press Mentions
Ocugen Announces First Patient Dosed in Phase 1/2 Trial of OCU410 Modifier Gene Therapy for GADecember 15th, 2023- Ocugen, Inc. Announces the First Patient Dosed in Phase 3June 21st, 2024
- Ocugen Doses First Patient with Gene Therapy for Retinitis Pigmentosa in Phase 3 TrialJuly 7th, 2024
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
